Prostate Cancer
Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancer.
September 14, 2024
SECuRE Trial Advances: No Dose Limiting Toxicities and Strong Preliminary Efficacy Data in First Multi-Dose Cohort
September 13, 2024
Homologous Recombination Repair Testing Patterns and Outcomes in mCRPC by Alteration Status and Race.
September 13, 2024
Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics.
September 13, 2024
Quantification of Gleason Pattern 4 Metrics Identifies Pathologic Progression in Patients With Grade Group 2 Prostate Cancer on Active Surveillance.
September 13, 2024
Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial.
September 13, 2024
YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer.
September 13, 2024
PIONEER big data platform for prostate cancer: lessons for advancing future real-world evidence research.
September 13, 2024
Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial.
September 13, 2024
Safety and feasibility of "three arms settings" robot-assisted radical prostatectomy using the Hugo RAS system: surgical set-up in a double-center large case series.
September 12, 2024
Moderately hypofractionated prostate-only versus whole-pelvis radiotherapy for high-risk prostate cancer: A retrospective real-world single-center cohort study.
September 12, 2024
Silver Nanoparticles (AgNPs) Uptake by Caveolae-Dependent Endocytosis is Responsible for Their Selective Effect Towards Castration Resistant Prostate Cancer.
September 12, 2024
Oncologic Outcomes of Incidental Versus Biopsy-diagnosed Grade Group 1 Prostate Cancer: A Multi-institutional Study.
September 12, 2024
Amiloride Sensitizes Prostate Cancer Cells to the Reversible Tyrosine Kinase Inhibitor Lapatinib by Modulating ERBB3 Subcellular Localization.
September 12, 2024